11 completed, 8 recruiting, 4 active not recruiting, 4 terminated. 18 Phase 3, 9 Phase 4, 5 Phase 2, 2 Phase 1, 1 Not applicable.
Follow emicizumab: new trials by email Literature Review of emicizumab trials Research Report on emicizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction efanesoctacog alpha, Emicizumab - Hemophilia A With Inhibitor | Phase 4 | Not yet recruiting | Versiti Blood Health | 15 | 2026-12-01 | 2026-07-27 |
| SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis Emicizumab, FEIBA, rFVIIa - Hemophilia A | Phase 3 | Withdrawn | Emory University | 2026-09-01 | 2026-11-06 | |
| TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies Half-life factor VIII based replacement therapy, Non-FVIII based replacement therapy - Hemophilia A, Factor VIII (FVIII) | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-07-22 | 2026-09-29 | |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A NXT007, Emicizumab - Hemophilia A | Phase 3 | Recruiting | Hoffmann-La Roche | 360 | 2026-04-27 | 2026-11-03 |
| A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates - Von Willebrand Disease, Type 3 | Phase 3 | Recruiting | Hoffmann-La Roche | 75 | 2025-06-27 | 2026-11-16 |
| Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients Emicizumab Injection, Factor VIII (FVIII) - Hemophilia A | Phase 2 / Phase 3 | Not yet recruiting | Dhaka Medical College | 20 | 2025-06-01 | 2025-04-22 |
| Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A Switching to low dose emicizumab - Hemophilia A Patient | Phase 2 / Phase 3 | Active not recruiting | Chulalongkorn University | 18 | 2025-06-01 | 2026-02-27 |
| Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A HEMLIBRA - Hemophilia A | Completed | Montefiore Medical Center | 71 | 2024-08-01 | 2025-09-08 | |
| A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) - Hemophilia A | Phase 4 | Recruiting | Sanofi | 20 | 2024-03-01 | 2026-09-23 |
| Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab Emicizumab - Hemophilia A | Unknown | Newark Beth Israel Medical Center | 50 | 2023-12-01 | 2023-10-30 | |
| Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis Emicizumab, FVIII - Hemophilia A | Recruiting | Wayne State University | 72 | 2023-08-16 | 2026-07-02 | |
| Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A "Emicizumab", "HEMLIBRA®" - Severe Hemophilia A Without Inhibitor, Joint Bleed | Phase 2 / Phase 3 | Unknown | Chulalongkorn University | 15 | 2023-06-22 | 2024-03-05 |
| Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A Emicizumab - Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia | Phase 1 | Recruiting | Bleeding and Clotting Disorders Institute Peoria, Illinois | 40 | 2022-11-01 | 2026-04-03 |
| Pharmacokinetic-guided Dosing of Emicizumab Emicizumab - PK-guided dose reduction, Emicizumab - Dosis continuation group, Emicizumab - Dose adjustment group - Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor | Phase 4 | Unknown | Kathelijn Fischer | 95 | 2022-09-08 | 2024-03-20 |
| Emicizumab in Patients With Acquired Hemophilia A emicizumab - Acquired Hemophilia A | Phase 2 | Active not recruiting | University of Washington | 51 | 2022-08-31 | 2025-11-05 |
| Hemlibra in Mild Hemophilia A Emicizumab - Factor VIII Deficiency, Congenital | Phase 4 | Recruiting | Indiana Hemophilia &Thrombosis Center, Inc. | 20 | 2022-07-25 | 2024-03-15 |
| A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis Emicizumab - Severe Hemophilia A, Moderate Hemophilia A | Phase 4 | Active not recruiting | Hoffmann-La Roche | 136 | 2022-06-20 | 2026-10-23 |
| Emicizumab PUPs and Nuwiq ITI Study Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol) - Hemophilia A | Phase 3 | Withdrawn | Emory University | 2022-02-17 | 2024-01-05 | |
| The Hemophilia Inhibitor Eradication Trial Eloctate ITI, Emicizumab - Hemophilia A With Inhibitor | Phase 3 | Terminated | Margaret Ragni | 1 | 2021-11-01 | 2023-02-21 |
| The Hemophilia Inhibitor Prevention Trial Eloctate Injectable Product, Emicizumab Injection [Hemlibra] - Hemophilia A Without Inhibitor | Phase 3 | Terminated | Margaret Ragni | 1 | 2021-10-11 | 2023-04-11 |
Showing 20 of 38. Sign in to see all of them.
Hemophilia A (33) · Factor 8 deficiency, acquired (2) · Hemarthrosis (2) · von Willebrand Disease, Type 3 (2) · Hematologic Diseases (1) · Hemophilia B (1) · Hemorrhage (1) · Hemostatic Disorders (1)
Hoffmann-La Roche (12) · Emory University (3) · Margaret Ragni (3) · Chulalongkorn University (2) · Genentech, Inc. (2) · Indiana Hemophilia &Thrombosis Center, Inc. (2) · University of Texas Southwestern Medical Center (2) · Bleeding and Clotting Disorders Institute Peoria, Illinois (1) · Children's Hospital Los Angeles (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Dhaka Medical College (1) · GWT-TUD GmbH (1) · Kathelijn Fischer (1) · Montefiore Medical Center (1) · Newark Beth Israel Medical Center (1)
United States (29) · Germany (11) · Spain (10) · United Kingdom (9) · Italy (8) · France (7) · South Africa (7) · Australia (6) · Belgium (6) · Canada (6) · Japan (6) · Poland (6) · Netherlands (5) · Brazil (4) · Taiwan (4)
Margaret V Ragni, MD, MPH (3) · Amy D Shapiro, MD (2) · Robert Sidonio, MD (2) · Akhil R. Biswas, MBBS, FCPS (1) · Andreas Tiede, Prof. Dr. (1) · Guy Young, MD (1) · Jennifer Davila, MD (1) · Jessica Garcia, MD (1) · Jonathan C Roberts, MD (1) · Meera Chitlur, MD (1) · Rebecca Kruse-Jarres, MD, MPH (1)
PMID 35939785, PMID 31697801, PMID 23731246, PMID 23815950, PMID 25059285, PMID 28691557, PMID 30157389, PMID 10968546, PMID 1202003, PMID 19995408, PMID 22530687, PMID 22733686, PMID 22776238, PMID 24628543, PMID 25854144, PMID 26674820, PMID 29296836, PMID 30430726, PMID 30997536, PMID 31003963, PMID 31003964, PMID 3418398, PMID 34435432, PMID 34589194, PMID 35905294, PMID 36636993, PMID 36716761, PMID 37858328, PMID 38127586, PMID 38222041, PMID 38853005, PMID 39737816, PMID 40795229, PMID 42290320, PMID 8141115, PMID 9873794
2016 (4), 2023 (3), 2015 (1), 2019 (1), 2025 (1)